Parkinson's Disease Neuroprotection Clinical Trial: Clinical Center

帕金森病神经保护临床试验：临床中心

基本信息

批准号：
8601323
负责人：
KAPIL D SETHI
金额：
$ 5.76万
依托单位：
AUGUSTA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-30 至 2014-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8601323
关键词：
Activities of Daily Living Adult Affect Age American Caring Chronic Clinic Clinical Clinical Trials Communities Controlled Clinical Trials Creatine Digit structure Disease Double-Blind Method England Enrollment Ensure European Union Fostering Futility Future Goals Health Health Sciences Health Services Individual Maintenance Measures Mental Depression Modality Movement Disorders National Institute of Neurological Disorders and Stroke Neurodegenerative Disorders Neuroprotective Agents Neurosciences North America Onset of illness Outcome Measure Parkinson Disease Participant Patients Pharmaceutical Preparations Phase Phase III Clinical Trials Placebo Control Placebos Population Process Protocols documentation Qualifying Quality of life Randomized Safety Support Groups Testing Therapeutic Equivalency Universities Visit Work cognitive function design disability follow-up neuroprotection operation outreach patient advocacy group prevent primary outcome programs treatment strategy

项目摘要

DESCRIPTION (provided by applicant): To successfully complete the NET-PD's current ongoing clinical trial. Summary: The Georgia Health Sciences University (GHSU) Movement Disorders Clinic (MDC) is a uniquely qualified and established clinical center for the proposed continuation of a large Phase III, randomized, double-blinded, placebo-controlled clinical trial, which seeks to evaluate the neuroprotective potential of creatine compared with placebo in over 1700 patients. GHSU is seeking support so as to continue all patient follow-up activities necessary for the successful completion of the creatine trial. Follow-up is expected to be completed in 2015. This project is aimed to evaluate the neuroprotective potential of a pharmacological agent designed to slow the progression of PD; the goal set forth by NINDS upon initiation of the NET-PD program. Long-Term Objectives: 1. To delay the progression of PD through the use of medications while maintaining quality of life. 2. Discover indicators of those susceptible to PD and prevent or delay onset of the disease. 3. Ultimately, find a cure for PD.

描述（由申请人提供）：成功完成NET-PD当前正在进行的临床试验。摘要：佐治亚州健康科学大学（GHSU）运动障碍诊所（MDC）是一个独特的合格且已建立的临床中心，用于拟议延续一项大型III期，随机，双眼，安慰剂对照的临床试验，旨在评估与1700年以上的蛋白酶的神经保护潜力。 GHSU正在寻求支持，以继续成功完成肌酸试验所需的所有患者后续活动。预计随访将于2015年完成。该项目旨在评估旨在减缓PD进展的药理学剂的神经保护潜力； NINDS启动Net-PD计划的目标。长期目标： 1。通过使用药物来延迟PD的进展，同时保持生活质量。 2。发现容易受PD的人的指标，并预防或延迟疾病发作。 3。最终，找到对PD的治疗方法。